Jan Theys

4.2k citations

98 papers · 3.1k indexed · h-index 36

Impact in

Biotechnology top 0.2%
- Cancer Research and Treatments
Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism

Papers in ⓘ

Biotechnology 41
- Cancer Research and Treatments 40
Cancer Research 30
- Cancer, Hypoxia, and Metabolism 23

Co-authors: Philippe Lambin (58 shared papers)Willy Landuyt (20 shared papers)Ludwig J. Dubois (37 shared papers)Marc Vooijs (16 shared papers)Sandra Nuyts (17 shared papers)Bradly G. Wouters (16 shared papers)Jozef Anné (17 shared papers)Lieve Van Mellaert (13 shared papers)
Journals: Radiotherapy and Oncology (14 papers)Cancers (5 papers)European Journal of Cancer (3 papers)Oncotarget (3 papers)British Journal of Cancer (3 papers)
Partner nations: Netherlands Belgium Germany

In The Last Decade

Jan Theys

96 papers receiving 3.1k citations

Peers

Countries citing papers authored by Jan Theys

Since Specialization

Citations

This map shows the geographic impact of Jan Theys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Theys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Theys more than expected).

Fields of papers citing papers by Jan Theys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Theys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Theys. The network helps show where Jan Theys may publish in the future.

Co-authors

The 25 scholars most cited alongside Jan Theys, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jan Theys Line = papers co-authored together Jan Theys links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells Radiotherapy and Oncology ·Jan Theys, Barry Jutten, R. Habets, Kim Paesmans, Arjan J. Groot, Philippe Lambin, Bradly G. Wouters, Guido Lammering, Marc Vooijs	2011	185
2	Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? Frontiers in Oncology ·Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys, Marc Vooijs	2018	162
3	Hypoxia as a target for combined modality treatments European Journal of Cancer ·Bradly G. Wouters, Sherry A. Weppler, Marianne Koritzinsky, Willy Landuyt, Sandra Nuyts, Jan Theys, Roland K. Chiu, Philippe Lambin	2002	140
4	Lysine 63-Polyubiquitination Guards against Translesion Synthesis–Induced Mutations PLoS Genetics ·Roland K. Chiu, J Brun, Chantal H.M.A. Ramaekers, Jan Theys, Lin Weng, Philippe Lambin, Douglas A. Gray, Bradly G. Wouters	2006	107
5	Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo British Journal of Cancer ·Jan Theys, Oliver Pennington, Ludwig J. Dubois, Gill Anlezark, Thomas E. Vaughan, Asferd Mengesha, Willy Landuyt, Jozef Anné, Philip J. Burke, Peter Dürre, Bradly G. Wouters, Nigel P. Minton, Philippe Lambin	2006	98
6	Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation Gene Therapy ·Sandra Nuyts, Lieve Van Mellaert, Jan Theys, Willy Landuyt, E. Bosmans, Jozef Anné, Philippe Lambin	2001	89
7	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials Clinical and Translational Radiation Oncology ·Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk De Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois	2019	89
8	Combining radiotherapy with immunotherapy: the past, the present and the future British Journal of Radiology ·Evert J. Van Limbergen, Dirk K. De Ruysscher, Verónica Olivo Pimentel, Damiënne Marcus, Maaike Berbée, Ann Hoeben, Nicolle H. Rekers, Jan Theys, Ala Yaromina, Ludwig J. Dubois, Philippe Lambin	2017	89
9	Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum Cancer Gene Therapy ·Jan Theys, Willy Landuyt, Sandra Nuyts, Lieve Van Mellaert, A. van Oosterom, Philippe Lambin, Jozef Anné	2001	75
10	Colonisation ofClostridiumin the body is restricted to hypoxic and necrotic areas of tumours Anaerobe ·Philippe Lambin, Jan Theys, Willy Landuyt, Paul F.J.W. Rijken, Albert van der Kogel, E. van der Schueren, R.J. Hodgkiss, Jack Fowler, Sandra Nuyts, Ernst de Bruijn, Lieve Van Mellaert, Jozef Anné	1998	73
11	Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated salmonella Cancer Biology & Therapy ·Asferd Mengesha, Ludwig J. Dubois, Philippe Lambin, Willy Landuyt, Roland K. Chiu, Bradly G. Wouters, Jan Theys	2006	70
12	In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment International Journal of Radiation OncologyBiologyPhysics ·Willy Landuyt, Bisan Ahmed, Sandra Nuyts, Jan Theys, Michel Op de Beeck, Alex Rijnders, Jozef Anné, A. van Oosterom, Walter Van den Bogaert, Philippe Lambin	2001	67
13	Regulated Proteolysis of NOTCH2 and NOTCH3 Receptors by ADAM10 and Presenilins Molecular and Cellular Biology ·Arjan J. Groot, R. Habets, Sanaz Yahyanejad, Caroline Hodin, Karina Reiß, Paul Säftig, Jan Theys, Marc Vooijs	2014	67
14	Secretory production of biologically active rat interleukin-2 byClostridium acetobutylicumDSM792 as a tool for anti-tumor treatment FEMS Microbiology Letters ·Sofie BarbÃ©, Lieve Van Mellaert, Jan Theys, Nick Geukens, Elke Lammertyn, Philippe Lambin, Jozef AnnÃ©	2005	66
15	Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo Oncotarget ·John Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M. Kubiak, Ludwig J. Dubois, Kim Paesmans, Lieve Van Mellaert, Richard J. Knox, Sarah A. Kuehne, Philippe Lambin, Nigel P. Minton	2014	64
16	Vascular targeting of solid tumours European Journal of Cancer ·Willy Landuyt, O Verdoes, D.O Darius, M. Drijkoningen, Sandra Nuyts, Jan Theys, L Stockx, Wim Wynendaele, Jack F. Fowler, Geert Maleux, W. Van den Bogaert, Jozef Anné, A. van Oosterom, Philippe Lambin	2000	60
17	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma Oncotarget ·Sanaz Yahyanejad, Henry King, Venus Sosa Iglesias, Patrick V. Granton, Lydie M.O. Barbeau, Stefan J. van Hoof, Arjan J. Groot, R. Habets, Jos Prickaerts, Anthony J. Chalmers, Daniëlle B. P. Eekers, Jan Theys, Susan Short, Frank Verhaegen, Marc Vooijs	2016	58
18	StableEscherichia coli-Clostridium acetobutylicumShuttle Vector for Secretion of Murine Tumor Necrosis Factor Alpha Applied and Environmental Microbiology ·Jan Theys, Sandra Nuyts, Willy Landuyt, Lieve Van Mellaert, C Dillen, Michael Böhringer, Peter Dürre, Philippe Lambin, Jozef Anné	1999	56
19	High NOTCH activity induces radiation resistance in non small cell lung cancer Radiotherapy and Oncology ·Jan Theys, Sanaz Yahyanejad, R. Habets, Paul N. Span, Ludwig J. Dubois, Kim Paesmans, Bo Kattenbeld, Jack P.M. Cleutjens, Arjan J. Groot, Olga C.J. Schuurbiers, Philippe Lambin, Johan Bussink, Marc Vooijs	2013	55
20	The Use of Radiation-Induced Bacterial Promoters in Anaerobic Conditions: A Means to Control Gene Expression inClostridium-Mediated Therapy for Cancer Radiation Research ·Sandra Nuyts, Lieve Van Mellaert, Jan Theys, Willy Landuyt, Philippe Lambin, Jozef Anné	2001	55

About Jan Theys

Jan Theys is a scholar working on Biotechnology, Cancer Research, Genetics, Oncology and Genetics, having authored 98 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer Research and Treatments (40 papers), Cancer, Hypoxia, and Metabolism (23 papers), Virus-based gene therapy research (22 papers), Nanoplatforms for cancer theranostics (10 papers), Bacteriophages and microbial interactions (10 papers), Cancer Cells and Metastasis (6 papers), Glioma Diagnosis and Treatment (5 papers) and Epigenetics and DNA Methylation (5 papers). The work is most often cited by research in Biotechnology (1.0k citations), Cancer Research (766 citations), Oncology (679 citations), Genetics (656 citations) and Molecular Biology (1.3k citations). Jan Theys has collaborated with scholars based in Netherlands, Belgium and Germany. Frequent co-authors include Philippe Lambin, Willy Landuyt, Ludwig J. Dubois, Marc Vooijs, Sandra Nuyts, Bradly G. Wouters, Jozef Anné, Lieve Van Mellaert, Roland K. Chiu and Arjan J. Groot. Their work appears in journals such as Radiotherapy and Oncology, Cancers, European Journal of Cancer, Oncotarget and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact